Company intelligence / Profile preview

Koniku

San Rafael, California, United States

Ownership: Private
Development stage: Other

Overview

Koniku develops biohybrid devices that combine synthetic neurobiology with silicon to detect and analyze a wide range of volatile organic compounds, with primary applications in security (explosives, drugs), environmental monitoring, and agriculture (food quality). Their technology is positioned as a sensory platform, not a therapeutic or pharmaceutical product, and is not in clinical development for human treatment. The company is at an early, R&D-focused stage with a focus on commercialization in non-therapeutic sectors.

Therapeutic areas: OtherInfectious Diseases
Modalities: Device
Industry: Non-Drug Biotech

Beyond the preview

Go deeper on Koniku.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Koniku.

Explore the full profile